References
- Arbelaez MP, Nelson KE, Munoz A. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. Int J Epidemiol. 2000;29:1085–1091.
- Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb). 2012;92:S6–S13.
- Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tuber Lung Dis. 1992;73:252–261.
- Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42:548–558.
- Heiman S, Weil M, Shulman LM, et al. Co-appearance of OPV and BCG vaccine-derived complications in two infants with severe combined immunodeficiency. Immunol Res. 2018;66:437–443.
- Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133:961–966.
- Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133:1134–1141.
- Norouzi S, Aghamohammadi A, Mamishi S, et al. Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect. 2012;64:543–554.
- Ninane J, Grymonprez A, Burtonboy G, et al. Disseminated BCG in HIV infection. Arch Dis Child. 1988;63:1268–1269.
- Lee WI, Huang JL, Yeh KW, et al. Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs). J Formos Med Assoc. 2011;110:750–758.
- Zhou Q, Hui X, Ying W, et al. A cohort of 169 chronic granulomatous disease patients exposed to BCG vaccination: a retrospective study from a single center in Shanghai, China (2004–2017). J Clin Immunol. 2018;38:260–272.
- Awad R. BCG vaccine and post-BCG complications among infants in Gaza Strip, 1999. East Mediterr Health J. 2001;7:211–220.
- Daoud W. Control of an outbreak of BCG complications in Gaza. Respirology 2003;8:376–378.
- Shearer WT, Dunn E, Notarangelo LD, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133:1092–1098.
- Ying W, Sun J, Liu D, et al. Clinical characteristics and immunogenetics of BCGos is/BCGitis in Chinese children: a 6 year follow-up study [research support, non-U.S. Gov't]. PLoS One 2014;9:e94485.
- Rechavi E, Lev A, Simon AJ, et al. First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights. Front Immunol. 2017;8:1448.
- Sadeghi-Shanbestari M, Ansarin K, Maljaei SH, et al. Immunologic aspects of patients with disseminated Bacille Calmette-Guerin disease in north-west of Iran. Ital J Pediatr. 2009;35:42.